Looks like you’re on the UK site. Choose another location to see content specific to your location
Siemens and Insightec announce new MRI-focused collaboration
Siemens Healthineers has announced a new partnership with Insightec, a leading provider of magnetic resonance imaging (MRI)-guided focused ultrasound therapy.
The collaboration will focus on the development of compatibility between the Exablate Neuro system and Siemens' leading 1.5T and 3T clinical MRI systems, Magnetom Aera and Skyra. Both parties will work to provide access to Exablate Neuro for their installed customer base, as well as new clients.
Exablate Neuro is the world's first device for non-invasive application of MRI-guided focused ultrasound to be approved in the US and EU for the treatment of essential tremors and other conditions.
It uses focused ultrasound waves to precisely target and accurately ablate tissue deep within the brain without the need for incisions, and while minimising damage to adjacent healthy tissue.
Dr Christoph Zindel, senior vice-president and general manager of Siemens Healthineers' magnetic resonance business, said: "This strategic partnership of two leading organisations is exciting and further underlines Siemens Healthineers' strategy of enabling better patient outcomes by broadening its diagnostic imaging portfolio into advanced therapies in the area of neurological and other disorders."
Clinical research, development and regulatory approvals for Exablate Neuro are ongoing for additional neurosurgical applications and markets.
With over 20 years of experience within the science market, we at Zenopa have the knowledge skill and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard